Related Experiment Video
Updated: Dec 23, 2025
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis
Eric Deconinck1, Tony Petrella2, Francine Garnache Ottou3
1Service Hématologie, Université de Bourgogne Franche-Comté, INSERM Unite Mixte de Recherche (UMR) 1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Centre Hospitalier Universitaire de Besançon, 3 Boulevard Alexandre Fleming, Besançon Cedex 25030, France.
Insights
Physicians can identify blastic plasmacytoid dendritic cell neoplasm (BPDCN) by recognizing key clinical and biological signs. Accurate diagnosis relies on specific immunophenotyping and pathological analysis of lesions.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy.
- Clinical and biological presentations of BPDCN can be diverse, posing diagnostic challenges for clinicians.
Purpose of the Study:
- To outline the diagnostic criteria for BPDCN.
- To highlight clinical and biological features that may alert physicians to this rare neoplasm.
Main Methods:
- Review of clinical and biological data from BPDCN patients.
- Immunophenotyping of blood or bone marrow aspirates using a panel of markers including CD4, CD56, HLA-DR, myeloid/lymphoid lineage markers, and plasmacytoid dendritic cell (pDC)-specific markers (CD123, cTCL1, CD303, CD304).
- Pathologic analysis of cutaneous lesions using immunohistochemistry with BPDCN-specific markers.
Main Results:
- Diagnostic criteria involve specific immunophenotypic profiles and/or pathological findings in cutaneous lesions.
- The combination of CD4, CD56, and pDC markers is crucial for immunophenotyping.
- Immunohistochemistry on tissue biopsy is essential for confirming cutaneous involvement.
Conclusions:
- Early recognition of BPDCN requires awareness of its varied presentations.
- Accurate diagnosis necessitates a multi-faceted approach combining immunophenotyping and histopathology.
- Utilizing specific pDC markers enhances diagnostic sensitivity for BPDCN.
Abstract:
Clinical and biological presentation of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) is depicted to highlight criteria that might alert physicians. Diagnosis of BPDCN is still challenging and requires (1) immunophenotyping of blood or bone marrow aspiration using several markers (CD4, CD56, HLA-DR, myeloid and lymphoid lineage markers) and should include pDC markers such as CD123, cTCL1, CD303, and CD304, and/or (2) pathologic analysis of cutaneous lesions, also with immunohistochemistry using markers specific to BPDCN.
